Laboratory Products
PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs
Sep 26 2018
Shuwen Biotech is the first in China to launch a locally manufactured proprietary PD-L1 test kit, which can accurately determine the expression status of PD-L1 in tumour tissues, and to provide laboratory testing services for anti-PD-L1/PD-1 drug development.
Recently, the investigation of the safety, efficacy and molecular marker efficacy of Hengrui Medicince’s anti-PD-1 drug, SHR1210, in the treatment of patients with advanced oesophageal squamous cell carcinoma who failed conventional therapy was published in the March 2018 issue of Clinical Cancer Research, in which one of Shuwen Biotech’s PD-L1 detection kits was used and clinical results showed that patients positive for PD-L1 (PD-L1 expression ≥ 5%) have a higher objective response rate.
Shuwen Biotech’s PD-L1 kits and testing services have been used by leading pharmaceutical companies for dozens of clinical trials against PD-1 immunotherapeutics, contributing to the development of tumour immunotherapy drugs. Shuwen Biotech's CAP-certified Shuwen Guanz Diagnostic Laboratories also successfully passed CAP’s multi-site, multi-country proficiency testing for PD-L1 testing.
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Sep 22 2024 Messina, Italy
19th Confocal Raman Imaging Symposium
Sep 23 2024 Ulm, Germany
Sep 24 2024 Kielce, Poland
WoTS - World of Technology and Science
Sep 24 2024 Utrecht, Holland
Sep 25 2024 Frankfurt am Main, Germany